Purchase this article with an account.
E. Torres-Porras, O. Burgos-Vejar, H. Ruiz-García, R. Velez-Montoya, A. Pérez-Montesinos, D. Rascón-Vargas, V. Franco-Cárdenas, G. García-Aguirre, J. Dalma-Weiszhausz, V. Morales-Cantón; Prevention of Post-Photocoagulation Related Macular Edema by Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2009;50(13):225.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the efficacy of intravitreal bevacizumab in preventing macular edema secondary to panretinal photocoagulation (PRP) in patients with proliferative diabetic retiniopathy (PDR).
We enrolled 8 patients with PDR and no macular edema. One randomly selected eye received a single bevacizumab dose between laser sessions. We measured the central retinal thickness (CRT) by Optical Coherence Tomography (OCT) and the best corrected visual acuity (BCVA) in ETDRS charts at base line and 12 weeks after PRP completion.
Average BCVA of the injected eye at baseline was 75.6±6.6 letters which improved to 79.5±8.5 12 weeks post treatment. The fellow eye showed a baseline BCVA of 79.0±9.1 letters and 80.7±2.5. 12 weeks post treatment. Average CRT in the injected eye at baseline: 208.38±28.7 µm, 12 weeks: 222.0±16.8 µm. Fellow-eye: 193.75±29.8 µm, 12 week: 206.25±23.6µm. There were no statistically significant differences between any of the measurements. (p > 0.05).
There appears to be no difference between a single intravitreal dose of bevacizumab and no treatment in preventing macular edema secondary to PRP. A greater number of patients are required before more specific conclusions can be drawn.
Clinical Trial: :
This PDF is available to Subscribers Only